Skip to main content
. 2022 Nov 17;2022(11):CD014963. doi: 10.1002/14651858.CD014963.pub2

EUCTR2020‐004323‐16.

Methods Trial design: randomised, multicentre, double‐blind study
Sample size: 260
Setting: inpatient
Language: Italian, English
Number of centres: 5
Type of intervention (treatment/prevention): treatment
Participants Inclusion criteria
  • Age = 18 years

  • Informed consent for participation in the study and for data processing

  • Molecular diagnosis with PCR test of Sars‐CoV2 infection

  • Hospitalisation in a specialist ward for COVID‐19 patient care (e.g. Infectious Diseases, Pulmonology or Internal Medicine)

  • Need for supplemental oxygen in any delivery mode with the exception of IMV

  • PaO2/FiO2 between 100 and 300 mmHg

  • Clinical/instrumental diagnosis (high‐resolution chest CT scan or chest X‐ray or lung ultrasound) of interstitial pneumonia for no more than 3 days

  • Serum CRP > 5 mg/dL

  • Interval from onset of SARS‐CoV2 infection symptoms to randomisation > 5 days


Exclusion criteria
  • IMV

  • Presence of shock or concomitant organ failure that requires admission to the ICU

  • Pregnancy or breastfeeding

  • Severe heart or kidney failure

  • Known hypersensitivity to methylprednisolone, to dexamethasone or to an exception

  • Diabetes not compensated according to the doctor's judgement

  • Other clinical conditions that contraindicate methylprednisolone and cannot be treated or resolved according to the doctor's judgement

  • Steroid bolus therapy in the week prior to enrolment for the study

  • Enrolment in another clinical trial

  • Patient already randomised in this study

Interventions Details of intervention:
  • Dose: methylprednisolone (1 g/d for 3 days)

  • Route of administration: IV


Treatment details of control group (e.g. dose, route of administration): placebo, IV
Concomitant therapy: no information
Outcomes Primary study outcome: length of hospitalisation, calculated as the interval between randomisation and discharge from the hospital without the need for supplemental oxygen
Notes Recruitment status: completed
Prospective completion date: 4‐month trial duration planned
Date last update was posted: 25 November 2020
Sponsor/funding: Azienda Ospedaliera Arcispedale Santa Maria Nuova/IRCCS Di Reggio Emilia